<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093505</url>
  </required_header>
  <id_info>
    <org_study_id>NCT-2017-0537</org_study_id>
    <nct_id>NCT04093505</nct_id>
  </id_info>
  <brief_title>Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)</brief_title>
  <acronym>GnG</acronym>
  <official_title>Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Intensive Postremission Therapy Double Blinded With or Without Glasdegib in Older Patients With Newly Diagnosed AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized phase III trial with a 2x2 factorial design with measurable&#xD;
      residual disease and event-free survival as primary endpoints, respectively. Patients are&#xD;
      upfront randomized for the two induction schedules (Gemtuzumab Ozogamicin (GO)-147 versus&#xD;
      GO-1; ratio 1:1) and for Glasdegib or Placebo (double blinded, ratio 1:1) as adjunct to&#xD;
      consolidation therapy and as single agent 6 months maintenance therapy. Chemotherapy backbone&#xD;
      for induction therapy is standard 7+3 with cytarabine 200mg/m² continuously day 1 to day 7,&#xD;
      daunorubicin 60mg/m² days 1, 2 and 3 and for consolidation therapy intermediate dose&#xD;
      cytarabine (1g/m², bi-daily, days 1,2,3). The trial is designed to gain evidence of&#xD;
      anti-leukemic activity of GO and Glasdegib in older patients with newly diagnosed acute&#xD;
      myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The two research questions are addressed in a 2 by 2 factorial design. Patients are upfront randomized for the two induction schedules (GO-147 versus GO-1, ratio 1:1) and for Glasdegib or Placebo (double blinded, ratio 1:1) as adjunct to consolidation therapy and as single agent 6 months maintenance therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD-negativity</measure>
    <time_frame>Collected during the first MRD-analysis after the first induction therapy cycle (after 4 weeks)</time_frame>
    <description>Minimal Residual Disease negativity (MRD-negativity) after induction therapy measured by flow cytometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EFS</measure>
    <time_frame>Collected after 2 years follow-up time</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>GO147_G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7&#xD;
_G: Consolidation &amp; Maintenance therapy Glasdegib 100mg on days 4 to 27</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GO147_P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7&#xD;
_P: Consolidation &amp; Maintenance therapy Placebo 100mg on days 4 to 27</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GO1_G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1&#xD;
_G: Consolidation &amp; Maintenance therapy Glasdegib 100mg on days 4 to 27</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GO1_P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1&#xD;
_P: Consolidation &amp; Maintenance therapy Placebo 100mg on days 4 to 27</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin 147</intervention_name>
    <description>Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7</description>
    <arm_group_label>GO147_G</arm_group_label>
    <arm_group_label>GO147_P</arm_group_label>
    <other_name>GO147</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemtuzumab Ozogamicin 1</intervention_name>
    <description>Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1</description>
    <arm_group_label>GO1_G</arm_group_label>
    <arm_group_label>GO1_P</arm_group_label>
    <other_name>GO1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glasdegib</intervention_name>
    <description>Consolidation &amp; Maintenance therapy Glasdegib 100mg on days 4 to 27</description>
    <arm_group_label>GO147_G</arm_group_label>
    <arm_group_label>GO1_G</arm_group_label>
    <other_name>_G</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Consolidation &amp; Maintenance therapy Placebo 100mg on days 4 to 27</description>
    <arm_group_label>GO147_P</arm_group_label>
    <arm_group_label>GO1_P</arm_group_label>
    <other_name>_P</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly diagnosed acute myeloid leukemia according to the 2016 WHO&#xD;
             classification&#xD;
&#xD;
          -  Genetic and immunophenotypic assessment in one of the central laboratories&#xD;
&#xD;
          -  No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (≤&#xD;
             7 days)&#xD;
&#xD;
          -  Age ≥ 60 years, no upper age limit&#xD;
&#xD;
          -  ECOG performance status (ECOG PS) ≤ 2. See appendix 18.1&#xD;
&#xD;
          -  Pregnancy and childbearing potential:&#xD;
&#xD;
               -  Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a&#xD;
                  negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL&#xD;
                  within 72 hours prior to registration (&quot;Women of childbearing potential&quot; is&#xD;
                  defined as a sexually active mature woman who has not undergone a hysterectomy or&#xD;
                  who has had menses at any time in the preceding 24 consecutive months).&#xD;
&#xD;
               -  Female patients of reproductive age must agree to avoid getting pregnant while on&#xD;
                  therapy.&#xD;
&#xD;
               -  WOCBP must either commit to continued abstinence from heterosexual intercourse or&#xD;
                  begin one acceptable method of birth control (IUD, tubal ligation, or partner's&#xD;
                  vasectomy) during study and 6 months after end of study/treatment. Hormonal&#xD;
                  contraception is an inadequate method of birth control.&#xD;
&#xD;
               -  Men must use a latex condom during any sexual contact with women of childbearing&#xD;
                  potential, even if they have undergone a successful vasectomy and must agree to&#xD;
                  avoid to father a child during study and 6 months after end of study/treatment&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
          -  Ability of patient to understand character and consequences of the clinical trial&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  AML with PML-RARA or BCR-ABL1&#xD;
&#xD;
          -  Patients with known active central nervous system leukemia (assessed clinically).&#xD;
&#xD;
          -  Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent for&#xD;
             AML. (Treatment of a preceding MDS (myelodysplastic syndrome) with HMA is not an&#xD;
             exclusion criterion.)&#xD;
&#xD;
          -  Inadequate renal function: creatinine &gt; 1.5 x upper normal serum level; estimated&#xD;
             creatinine clearance ≤30 ml/min (calculated using the standard method for the&#xD;
             institution).&#xD;
&#xD;
          -  Inadequate liver function: ALT and AST ≥ 2.5 x ULN), total bilirubin ≥ 1.5 x ULN;&#xD;
             Alkaline phosphatase ≥ 2.5 x ULN. Known liver cirrhosis or history of veno-occlusive&#xD;
             disease (VOD) or history of Sinusoidal Obstruction Syndrome (SOS)&#xD;
&#xD;
          -  Uncontrolled hypertension; severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
          -  Any one of the following ongoing or in the previous 6 months: myocardial infarction,&#xD;
             congenital long QT syndrome, Torsades de pointes, arrhythmias (including sustained&#xD;
             ventricular tachyarrhythmia), right or left bundle branch block and bifascicular&#xD;
             block, unstable angina, coronary/peripheral artery bypass graft, symptomatic&#xD;
             congestive heart failure (CHF NYHA III/IV), cerebrovascular accident, transient&#xD;
             ischemic attack or symptomatic pulmonary embolism; as well as bradycardia defined as&#xD;
             &lt;50 bpms&#xD;
&#xD;
          -  QTc interval &gt;470 msec using the Fredericia correction (QTcF).&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Patients known to be refractory to platelet or packed red cell transfusions as per&#xD;
             institutional guidelines, or who are known to refuse or who are likely to refuse blood&#xD;
             product support.&#xD;
&#xD;
          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin&#xD;
             cancer. Patients are not considered to have a &quot;currently active&quot; malignancy if they&#xD;
             have completed therapy for more than one year and are considered by their physician to&#xD;
             be at less than 30% risk of relapse within one year.&#xD;
&#xD;
          -  Severe neurologic or psychiatric disorder interfering with ability of giving informed&#xD;
             consent&#xD;
&#xD;
          -  Known or suspected active alcohol or drug abuse&#xD;
&#xD;
          -  Known positivity for HIV, active HBV, HCV, or hepatitis A infection&#xD;
&#xD;
          -  Evidence or history of severe non-leukemia associated bleeding diathesis or&#xD;
             coagulopathy&#xD;
&#xD;
          -  No consent for biobanking and for registration, storage and processing of the&#xD;
             individual disease-characteristics and course as well as information of the family&#xD;
             physician about study participation.&#xD;
&#xD;
          -  Pregnancy and lactation&#xD;
&#xD;
          -  History of hypersensitivity to the investigational medicinal product or to any drug&#xD;
             with similar chemical structure or to any excipient present in the pharmaceutical form&#xD;
             of the investigational medicinal product&#xD;
&#xD;
          -  Participation in a clinical study involving an investigational drug(s) (Phases 1-4)&#xD;
             within 4 weeks prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard F Schlenk, Prof. Dr.</last_name>
    <phone>0049 6221 56</phone>
    <phone_ext>6228</phone_ext>
    <email>Richard.schlenk@nct-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Internal Medicine V</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard F Schlenk, Prof. Dr.</last_name>
      <phone>+49 (0)6221 56</phone>
      <phone_ext>6228</phone_ext>
      <email>richard.schlenk@nct-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Tim Sauer, Dr.</last_name>
      <phone>+49 (0)6221 56</phone>
      <phone_ext>8030</phone_ext>
      <email>tim.sauer@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Richard F Schlenk, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>April 24, 2021</last_update_submitted>
  <last_update_submitted_qc>April 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Richard F Schlenk</investigator_full_name>
    <investigator_title>Head of NCT Trials Center and Clinical Trials Office Hematology/Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

